What agilon health inc. Investors Should Keep in Mind

By Kim Brooks • Sunday, December 03 16:21 • Permanent Link

Shares of Medical Distribution company agilon health inc. jumped 6.2% today. With many investors piling into AGL without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

AGL has an average analyst rating of buy and is -49.93% away from its mean target price of $22.53 per share
Its trailing earnings per share (EPS) is $-0.22
agilon health inc. has a trailing 12 month Price to Earnings (P/E) ratio of -51.3 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $0.03 and its forward P/E ratio is 376.0
The company has a Price to Book (P/B) ratio of 5.25 in contrast to the S&P 500's average ratio of 2.95
agilon health inc. is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-107985504, which refers to the total sum of all its inflows and outflows of cash over the last quarter
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2022, it served approximately 269,500 medicare advantage members and 89,000 Medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.